UK markets close in 2 hours 14 minutes

Tiziana Life Sciences Ltd (TLSA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4201-0.0120 (-2.78%)
As of 09:57AM EDT. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

    Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studiesNeuroinflammation modulation may be synergistic to approved treatments in Alzheimer’s Disease NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-

  • Globe Newswire

    Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

    NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in mi

  • Globe Newswire

    Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

    NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD